- Home
- LEO vs IOVA Comparison
LEO vs IOVA Comparison
Compare LEO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- IOVA
- Stock Information
- Founded
- LEO 1987
- IOVA 2007
- Country
- LEO United States
- IOVA United States
- Employees
- LEO N/A
- IOVA N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEO Finance
- IOVA Health Care
- Exchange
- LEO Nasdaq
- IOVA Nasdaq
- Market Cap
- LEO 363.8M
- IOVA 771.4M
- IPO Year
- LEO N/A
- IOVA N/A
- Fundamental
- Price
- LEO $5.94
- IOVA $1.89
- Analyst Decision
- LEO
- IOVA Buy
- Analyst Count
- LEO 0
- IOVA 10
- Target Price
- LEO N/A
- IOVA $12.22
- AVG Volume (30 Days)
- LEO 200.2K
- IOVA 11.2M
- Earning Date
- LEO 01-01-0001
- IOVA 08-07-2025
- Dividend Yield
- LEO 4.01%
- IOVA N/A
- EPS Growth
- LEO N/A
- IOVA N/A
- EPS
- LEO 0.04
- IOVA N/A
- Revenue
- LEO N/A
- IOVA $212,679,000.00
- Revenue This Year
- LEO N/A
- IOVA $86.62
- Revenue Next Year
- LEO N/A
- IOVA $69.95
- P/E Ratio
- LEO $152.00
- IOVA N/A
- Revenue Growth
- LEO N/A
- IOVA 11070.12
- 52 Week Low
- LEO $4.98
- IOVA $1.64
- 52 Week High
- LEO $6.50
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- LEO 59.01
- IOVA 47.70
- Support Level
- LEO $5.90
- IOVA $1.68
- Resistance Level
- LEO $6.00
- IOVA $1.82
- Average True Range (ATR)
- LEO 0.05
- IOVA 0.11
- MACD
- LEO 0.02
- IOVA 0.02
- Stochastic Oscillator
- LEO 73.91
- IOVA 51.14
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.